ACVC Premium Access

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – CON.

Presentation

About the speaker

Professor Christopher B Granger

Duke University Medical Center, Duke Clinical Research Institute, Durham (United States of America)
11 presentations
0 follower

5 more presentations in this session

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – PRO.

Speaker: Professor K. Huber (Vienna, AT)

Thumbnail

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – Discussion.

Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - PRO.

Speaker: Professor R. Welsh (Edmonton, CA)

Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - CON.

Speaker: Professor A. Kastrati (Munich, DE)

Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - Discussion.

Thumbnail

Access the full session

Debating Oral P2Y12 inhibitors Use – are there differences across the Atlantic?

Speakers: Professor C. Granger, Professor K. Huber, Professor R. Welsh, Professor A. Kastrati
Thumbnail

About the event

Image

ACVC 2021

13 March - 14 March 2021

Sessions Presentations

Related content

ACVC Premium Access

Cardiogenic shock: state of the art 2022 - discussion.

19 March 2022

ACVC Premium Access

Pathophysiology and evolving definition of cardiogenic shock.

19 March 2022

Open Access

Medical treatment depends on etiology!

18 March 2022

This platform is supported by

logo Novo Nordisk